Category Archives: Lymphoma/Myeloma

2. ASHupdate 2012, Non Hodgkin Lymphoma

Prof Stephen J Schuster, Direktor des Lymphoma Programmes des Abramson Cancer Centers in Philadelphia, USA, berichtet von den wichtigsten am ASH (American Society of Hematology) Meeting in Atlanta präsentierten Studien zum NHL (Non Hodgkin Lymphoma).

Teil 1:
Follikuläres Lymphom

– praktische Aspekte der 1. Linien-Behandlung in Anbetracht der neuen ASH-Daten
– wichtige Tyrosinkinase-Inhibitoren (Idelalisib, Ibrutinib), welche den Sprung in die Klinik schaffen werden (Phase III Studien laufen)

2nd ASHupdate 2012, Aggressive Lymphomas

Prof. Christoph Renner, medizinischer Onkologe am OnkoZentrum Hirslanden, OnkoZentrum Zürich und der Universität Basel, berichtet von wichtigen Studien zu aggressiven Lymphomen, welche am ASH (American Society of Hematology) Meeting in Atlanta vorgestellt wurden.

Aufgenommen am ASHupdate 2012 vom 20. Dezember in Zürich. Gesprächsleiter: Dr. med. Daniel Helbling.

1. ESMOupdate 2012, Lymphoma, Myeloma and CNS Tumors

Dr. med. Reinhard Zenhäuser und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Lymphoma, Myeloma and CNS Tumors, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:

1063 O: Sequential therapy with Brentuximab Vedotin in newly diagnosed patients with systemic Anaplastic large Cell Lymphoma (sALCL); M.A. Fanale et al

LBA15: Randomized multicenter phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolamide-based chemoradiation versus chemoradiation for unresectable glioblastoma (definitive results of the TEMAVIR ANOCEF study); B. Chauffert et al

4. ASCOupdate 2011, Lymphoma und Myeloma

Diskussionsleiter Dr. L. Widmer, OnkoZentrum Hirslanden, Zürich, bespricht folgende Studien:

Abstract 8000: R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma

Abstract 8002: Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL)

Abstract 8010: Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results

Abstract 8009: Secondary Malignancies Following Multiple Myeloma

Abstract LBA4: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma

Abstract LBA5: Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma